| Literature DB >> 28749164 |
Tomonori Kanda1, Yudai Nakai1,2, Akifumi Hagiwara1,2, Hiroshi Oba2,3, Keiko Toyoda2,3, Shigeru Furui3.
Abstract
In the 3 years since residual gadolinium-based contrast agent (GBCA) in the brain was first reported, much has been learned about its accumulation, including the pathway of GBCA entry into the brain, the brain distribution of GBCA and its excretion. Here we review recent progress in understanding the routes of gadolinium deposition in brain structures.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28749164 PMCID: PMC5963376 DOI: 10.1259/bjr.20170115
Source DB: PubMed Journal: Br J Radiol ISSN: 0007-1285 Impact factor: 3.039